Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Imidazole propionate and fibrosis in cardiometabolic diseases

Project description

Linking gut bacteria to fibrosis in heart and liver disease

Fibrosis is a condition where excessive scar tissue forms, leading to organ damage. It plays a major role in heart failure and liver disease, but the underlying aetiology remains poorly understood. The ERC-funded IMPACT project aims to investigate the role of imidazole propionate (ImP), a molecule produced by gut bacteria and linked to diabetes and heart disease. Researchers will study how ImP levels relate to fibrosis and uncover the molecular pathways involved. The work will also involve the development of inhibitors to block ImP production and treat fibrosis. By uncovering how gut bacteria affect organ health, this project could lead to better treatment for heart and liver diseases.

Objective

Fibrosis is a pathological feature caused by excessive extracellular matrix secretion, resulting in scar tissue that causes thickening and loss of tissue mobility, culminating in impaired organ function. It is a common feature of heart failure and non-alcoholic steatohepatitis and an important determinant of morbidity and mortality. However, relatively little is known about the underlying aetiology.
We and others have mapped alterations in the gut microbiota in different cardiometabolic diseases, focusing on the functions performed by the microbiota. IMPACT builds on our work showing that humans with type 2 diabetes have high plasma levels of the microbial metabolite imidazole propionate (ImP) and that ImP impairs insulin signalling through p38gamma. We also resolved the X-ray crystal structure of urocanate reductase (UrdA), the bacterial enzyme responsible for ImP production. Our recent work showed that ImP is more strongly associated with heart failure and that treatment of mice with ImP promotes both cardiac and liver fibrosis, consistent with studies showing that p38gamma signalling is implicated in fibrosis development.
IMPACT will first use state-of-the-art clinical assessments to determine how circulating levels of ImP correlate with fibrosis in heart and liver. Second, we will explore the kinetics by which ImP induces fibrosis in mice and how this process is associated with immune cell infiltration and disease progression. Third, to provide mechanistic understanding, we will perform similar experiments in mice lacking key target signalling components (e.g. p38gamma), combined with single cell sequencing that will guide us in producing tissue-specific knockouts to elucidate the cellular cross-talk. Fourth, we will generate UrdA inhibitors and test their potential to reduce ImP production in isolated bacteria, complex microbial communities, and colonised mice. Thus, IMPACT has the potential of generating new therapies to diseases with unmet clinical needs.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-ADG

See all projects funded under this call

Host institution

GOETEBORGS UNIVERSITET
Net EU contribution
€ 2 482 678,00
Address
VASAPARKEN
405 30 Goeteborg
Sweden
Region
Södra Sverige Västsverige Västra Götalands län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 482 678,00

Beneficiaries (1)